Orexo Full Year 2024 Earnings: EPS Misses Expectations

Orexo (STO:ORX) Full Year 2024 Results

Key Financial Results

• Revenue: kr590.0m (down 7.6% from FY 2023).
• Net loss: kr203.0m (loss widened by 58% from FY 2023).
• kr5.89 loss per share (further deteriorated from kr3.73 loss in FY 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Orexo EPS Misses Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 28%.

Looking ahead, revenue is forecast to grow 7.8% p.a. on average during the next 3 years, compared to a 28% growth forecast for the Pharmaceuticals industry in Sweden.

Performance of the Swedish Pharmaceuticals industry.

The company's shares are down 1.6% from a week ago.

Risk Analysis

We don't want to rain on the parade too much, but we did also find 3 warning signs for Orexo (1 is a bit unpleasant!) that you need to be mindful of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.